New Zealand markets closed

Hoth Therapeutics, Inc. (HOTH)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2200-0.0400 (-3.17%)
At close: 04:00PM EDT
1.2300 +0.01 (+0.82%)
After hours: 07:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.2600
Open1.3100
Bid1.1900 x 100
Ask1.2900 x 100
Day's range1.2175 - 1.3100
52-week range0.9900 - 4.3000
Volume28,175
Avg. volume475,303
Market cap5.964M
Beta (5Y monthly)0.61
PE ratio (TTM)N/A
EPS (TTM)-2.3000
Earnings date15 May 2024 - 19 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.67
  • PR Newswire

    Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023, having an exercise price of $5.00 per share, at a reduced exercise price of $1.6775 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant

  • PR Newswire

    Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai has identified a promising new therapeutic candidate, culminating in a strategic patent filing.

  • Zacks

    Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data

    Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.